Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0
|
作者：
Dickinson, Michael [1 ,2 ]
Carlo-Stella, Carmelo [3 ,4 ]
Morschhauser, Franck [5 ,6 ]
Bachy, Emmanuel [7 ]
Corradini, Paolo [8 ,9 ]
Iacoboni, Gloria [10 ]
Khan, Cyrus [11 ]
Wrobel, Thomasz [12 ]
Offner, Fritz [13 ]
Trneny, Marek [14 ]
Wu, Shang-Ju [15 ]
Cartron, Guillaume [16 ]
Hertzberg, Mark [17 ,18 ]
Sureda, Anna [19 ]
Perez-Callejo, David [20 ]
Lundberg, Linda [20 ]
Relf, James [21 ]
Clark, Emma [21 ]
Humphrey, Kathryn [21 ]
Hutchings, Martin [22 ]
机构：
[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Melbourne, Melbourne, Vic, Australia
[3] Humanitas Univ, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Milan, Italy
[5] Hop Claude Huriez, Lille, France
[6] CHU Lille, Lille, France
[7] Ctr Hosp Lyon Sud, Lyon, France
[8] Univ Milan, Milan, Italy
[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Allegheny Hlth Network, Pittsburgh, PA USA
[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland
[13] Univ Ziekenhuis Gent, Ghent, Belgium
[14] Charles Univ Hosp, Prague, Czech Republic
[15] Natl Taiwan Univ Hosp, Taipei, Taiwan
[16] CHU Montpellier, Montpellier, France
[17] Prince Wales Hosp, Sydney, NSW, Australia
[18] Univ New South Wales, Sydney, NSW, Australia
[19] Inst Catala Oncol Hosp, Barcelona, Spain
[20] F Hoffmann La Roche Ltd, Basel, Switzerland
[21] Roche Prod Ltd, Welwyn Garden City, Herts, England
[22] Rigshosp, Copenhagen, Denmark
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-478
引用
收藏
页码：S435 / S435
页数：1
相关论文
共 50 条
  • [31] Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study
    Coiffier, Bertrand
    Bosly, Andre
    Wu, Ka Lung
    Verhoef, Gregor
    Koen, Van Eygen
    Martinelli, Giovanni
    Barca, Gabriela
    Davies, Andrew
    Gallop-Evans, Eve
    Padmanabhan, Swaminathan
    Gupta, Ira V.
    Lin, Thomas S.
    Davis, Randy L.
    Losic, Nedjad
    Lisby, Steen
    Radford, John A.
    BLOOD, 2010, 116 (21) : 1613 - 1613
  • [32] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [33] A Phase I/II Study of a Hybrid Schedule of Flavopiridol in Relapsed/Refractory Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Dunleavy, Kieron
    Shapiro, Geoff
    Disinski, Megan
    Chirieac, Lucian
    Pittaluga, Stefania
    Jaffe, Elaine S.
    Janik, John E.
    Wiestner, Adrian
    Wilson, Wyndham H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (03): : E27 - E27
  • [34] Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Salles, Gilles
    Gopal, Ajay K.
    Minnema, Monique C.
    Wakamiya, Karen
    Feng, Huaibao
    Schecter, Jordan M.
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 275 - 284
  • [35] A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Collins, Graham P.
    Eyre, Toby A.
    Linton, Kim M.
    Radford, John
    Vallance, Grant D.
    Soilleux, Elizabeth
    Hatton, Chris
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (06) : 886 - 890
  • [36] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
    Bennani, N. Nora
    Nowakowski, Grzegorz
    Rimsza, Lisa M.
    Adjei, Alex A.
    Doyle, Laurence
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [37] A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Flinn, Ian W.
    Bartlett, Nancy L.
    Blum, Kristie A.
    Ardeshna, Kirit M.
    LaCasce, Ann S.
    Flowers, Christopher R.
    Shustov, Andrei R.
    Thress, Kenneth S.
    Mitchell, Patrick
    Zheng, Fred
    Skolnik, Jeffrey M.
    Friedberg, Jonathan W.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 11 - 17
  • [38] Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
    Morschhauser, Franck Andre
    Cartron, Guillaume
    Thieblemont, Catherine
    Solal-Celigny, Philippe
    Haioun, Corinne
    Bouabdallah, Reda
    Feugier, Pierre
    Bouabdallah, Krimo
    Asikanius, Elina
    Lei, Guiyuan
    Wenger, Michael
    Wassner-Fritsch, Elisabeth
    Salles, Gilles Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2912 - +
  • [39] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [40] Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab
    Sud, Rohit
    Friedberg, Jonathan W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (12): : 1776 - 1780
12345